{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:48:03Z","timestamp":1776779283813,"version":"3.51.2"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112940","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:21:31Z","timestamp":1760278891000},"page":"112940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Between Scylla and Charybdis \u2013 Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitus"],"prefix":"10.1016","volume":"229","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-3950","authenticated-orcid":false,"given":"Qidi","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/eurjpc\/zwac285","article-title":"Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990-2019: findings from 2019 global burden of disease study","volume":"30","author":"Li","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"25","key":"10.1016\/j.diabres.2025.112940_b0010","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2025.112940_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1264319","article-title":"High residual cardiovascular risk after lipid-lowering: prime time for predictive, preventive, personalized, participatory, and psycho-cognitive medicine","volume":"10","author":"Reijnders","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.diabres.2025.112940_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejim.2023.10.013","article-title":"Residual cardiovascular risk: when should we treat it?","volume":"120","author":"Gomez-Delgado","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"8","key":"10.1016\/j.diabres.2025.112940_b0025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabres.2025.112940_b0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2013the lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"6144","key":"10.1016\/j.diabres.2025.112940_b0035","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.diabres.2025.112940_b0040","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.diabres.2025.112940_b0045","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0050","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.diabres.2025.112940_b0055","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2025.112940_b0060","doi-asserted-by":"crossref","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol 2021:ATV0000000000000147. 10.1161\/ATV.0000000000000147.","DOI":"10.1161\/ATV.0000000000000147"},{"key":"10.1016\/j.diabres.2025.112940_b0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hlc.2022.11.015","article-title":"Australian atherosclerosis society position statement on lipoprotein(a): clinical and implementation recommendations","volume":"32","author":"Ward","year":"2023","journal-title":"Heart Lung Circ"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0075","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jacasi.2022.08.015","article-title":"Lipoprotein(a) and cardiovascular disease in Chinese population: a Beijing heart society expert scientific statement","volume":"2","author":"Li","year":"2022","journal-title":"JACC Asia"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0080","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0168-8227(02)00009-8","article-title":"Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients","volume":"56","author":"Nawawi","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.diabres.2025.112940_b0085","first-page":"107","article-title":"Determination of lipoprotein(a) concentrations and apolipoprotein(a) molecular weights in diabetic patients","volume":"26","author":"Ribault","year":"2000","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1016\/j.diabres.2025.112940_b0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1462-8902.2004.00352.x","article-title":"Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus","volume":"6","author":"Habib","year":"2004","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2025.112940_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf036","article-title":"Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease","author":"Kim","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12967-023-04836-7","article-title":"Risk factors for carotid plaque formation in type 2 diabetes mellitus","volume":"22","author":"Chen","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.diabres.2025.112940_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155347","article-title":"Circulating lipoprotein(a) levels and health outcomes: phenome-wide Mendelian randomization and disease-trajectory analyses","volume":"137","author":"Larsson","year":"2022","journal-title":"Metabolism"},{"issue":"8","key":"10.1016\/j.diabres.2025.112940_b0110","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db13-1144","article-title":"The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?","volume":"63","author":"Ye","year":"2014","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0125","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","article-title":"Lipoprotein(a) as a pharmacological target: premises, promises, and prospects","volume":"151","author":"Greco","year":"2025","journal-title":"Circulation"},{"issue":"10459","key":"10.1016\/j.diabres.2025.112940_b0130","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0135","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0140","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/HCO.0000000000001170","article-title":"Lipoprotein(a) is a highly atherogenic lipoprotein: pathophysiological basis and clinical implications","volume":"39","author":"Bj\u00f6rnson","year":"2024","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0145","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0150","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1161\/ATVBAHA.124.319483","article-title":"Lipoprotein(a) in the year 2024: a look back and a look ahead","volume":"44","author":"Tsimikas","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2025.112940_b0155","doi-asserted-by":"crossref","unstructured":"Tsamoulis D, Kosmas CE, Rallidis LS. Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine? Expert review of endocrinology & metabolism 2024;19(1):63-70. 10.1080\/17446651.2023.2293108.","DOI":"10.1080\/17446651.2023.2293108"},{"issue":"8033","key":"10.1016\/j.diabres.2025.112940_b0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07993-x","article-title":"Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis","volume":"634","author":"Takaoka","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.diabres.2025.112940_b0165","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.diabres.2025.112940_b0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabres.2025.112940_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0185","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5551\/jat.63587","article-title":"Effect of omega-3 fatty acid supplementation on the postprandial metabolism of apolipoprotein(a) in familial hypercholesterolemia","volume":"30","author":"Ying","year":"2023","journal-title":"J Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41569-023-00937-4","article-title":"Oxidized phospholipids in cardiovascular disease","volume":"21","author":"Tsimikas","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.diabres.2025.112940_b0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2025.112940_b0200","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-0716-4116-3_10","article-title":"A method for analysis of oxidized phospholipids from biological samples using mass spectrometry","volume":"2855","author":"Ghorasaini","year":"2025","journal-title":"Methods in Molecular Biology (Clifton, NJ)"},{"issue":"10","key":"10.1016\/j.diabres.2025.112940_b0205","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J Lipid Res"},{"issue":"10","key":"10.1016\/j.diabres.2025.112940_b0210","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0215","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J Lipid Res"},{"issue":"7709","key":"10.1016\/j.diabres.2025.112940_b0220","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-018-0198-8","article-title":"Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice","volume":"558","author":"Que","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.diabres.2025.112940_b0230","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.diabres.2025.112940_b0235","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/j.jacc.2024.08.070","article-title":"Oxidized phospholipids and calcificaortic valvular disease","volume":"84","author":"Bhatia","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0240","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.034774","article-title":"Lipoprotein(a), oxidized phospholipids, and progression to symptomatic heart failure: the CASABLANCA study","volume":"13","author":"Januzzi","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.diabres.2025.112940_b0245","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.diabres.2025.112940_b0250","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100585","article-title":"Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease","volume":"65","author":"Bellomo","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabres.2025.112940_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2023.08.004","article-title":"Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?","author":"Ward","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.diabres.2025.112940_b0265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.clnesp.2023.03.012","article-title":"Effect of omega-3 fatty acid ethyl esters on postprandial arterial elasticity in patients with familial hypercholesterolemia","volume":"55","author":"Ying","year":"2023","journal-title":"Clin Nutr ESPEN"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0270","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.jcmg.2019.06.022","article-title":"PCSK9 antibody alirocumab attenuates arterial wall inflammation without changes incirculating inflammatory markers","volume":"12","author":"Hoogeveen","year":"2019","journal-title":"J Am Coll Cardiol Img"},{"issue":"8","key":"10.1016\/j.diabres.2025.112940_b0275","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13442","article-title":"Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice","volume":"20","author":"Palmieri","year":"2021","journal-title":"Aging Cell"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0280","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmet.2019.10.014","article-title":"Neutralization of oxidized phospholipids ameliorates non-alcoholic steatohepatitis","volume":"31","author":"Sun","year":"2020","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0285","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/cvr\/cvy136","article-title":"Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids","volume":"115","author":"Yeang","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"24","key":"10.1016\/j.diabres.2025.112940_b0290","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0295","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.108.786822","article-title":"Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice","volume":"118","author":"Merki","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2025.112940_b0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.5433","article-title":"Olpasiran, oxidized phospholipids, and systemic inflammatory biomarkers: results from the OCEAN(a)-DOSE trial","author":"Rosenson","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.diabres.2025.112940_b0305","article-title":"The effects of colchicine on lipoprotein(a) and oxidized phospholipid associated cardiovascular disease risk","author":"Mohammadnia","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"10289","key":"10.1016\/j.diabres.2025.112940_b0310","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.diabres.2025.112940_b0315","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1096\/fj.202001451","article-title":"COVID-19-associated dyslipidemia: implications for mechanism of impaired resolution and novel therapeutic approaches","volume":"34","author":"Sorokin","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.diabres.2025.112940_b0320","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: the confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2025.112940_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.05.019","article-title":"High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner","author":"Assini","year":"2023","journal-title":"Atherosclerosis"},{"issue":"26","key":"10.1016\/j.diabres.2025.112940_b0330","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.diabres.2025.112940_b0335","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2018.05.029","article-title":"Inhibition of pericellular plasminogen activation by apolipoprotein(a): roles of urokinase plasminogen activator receptor and integrins \u03b1(M)\u03b2(2) and \u03b1(V)\u03b2(3)","volume":"275","author":"Romagnuolo","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabres.2025.112940_b0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2018.07.002","article-title":"Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells","volume":"169","author":"Romagnuolo","year":"2018","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0345","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0036-1598002","article-title":"Lipoprotein(a) as a risk factor for venous thromboembolism: a systematic review and meta-analysis of the literature","volume":"43","author":"Dentali","year":"2017","journal-title":"Semin Thromb Hemost"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0350","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2025.112940_b0355","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.wneu.2015.10.059","article-title":"An increased serum level of lipoprotein(a) is a predictor for deep vein thrombosis in patients with spinal cord injuries","volume":"87","author":"Wang","year":"2016","journal-title":"World Neurosurg"},{"issue":"22","key":"10.1016\/j.diabres.2025.112940_b0360","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0365","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11239-018-1769-0","article-title":"Elevated lipoprotein(a) as a new risk factor of cerebral venous sinus thrombosis: association with fibrin clot properties","volume":"47","author":"Skuza","year":"2019","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"10.1016\/j.diabres.2025.112940_b0370","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1161\/01.CIR.0000087598.05977.45","article-title":"Cerebral venous thrombosis in children: a multifactorial origin","volume":"108","author":"Heller","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0375","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2009.11.006","article-title":"High lipoprotein (a) levels are associated with an increased risk of retinal vein occlusion","volume":"210","author":"Sofi","year":"2010","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.diabres.2025.112940_b0380","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1016\/j.jcjo.2023.10.007","article-title":"Lack of association between Lp(a) and retinal vein occlusion in a single institution and US national database","volume":"59","author":"Russell","year":"2024","journal-title":"Can J Ophthalmol J Canadien d'ophtalmologie"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0385","first-page":"1770","article-title":"Lipoprotein(a) and thromboembolism: current state of knowledge and unsolved issues","volume":"20","author":"Konieczy\u0144ska","year":"2024","journal-title":"Arch Med Sci"},{"issue":"10","key":"10.1016\/j.diabres.2025.112940_b0390","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1073\/pnas.84.10.3224","article-title":"Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen","volume":"84","author":"Eaton","year":"1987","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0395","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/BF00282175","article-title":"The apolipoprotein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen","volume":"79","author":"Frank","year":"1988","journal-title":"Hum Genet"},{"issue":"6222","key":"10.1016\/j.diabres.2025.112940_b0400","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/339301a0","article-title":"A potential basis for the thrombotic risks associated with lipoprotein(a)","volume":"339","author":"Miles","year":"1989","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.diabres.2025.112940_b0405","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1021\/bi00068a021","article-title":"Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation","volume":"32","author":"Ezratty","year":"1993","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.diabres.2025.112940_b0410","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.diabres.2025.112940_b0415","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1111\/j.1538-7836.2005.01517.x","article-title":"Effects of high plasma lipoprotein (a) levels on tissue factor pathway inhibitor and the protein C pathway","volume":"3","author":"Di Nisio","year":"2005","journal-title":"J Thrombosis Haemostasis : JTH"},{"issue":"27","key":"10.1016\/j.diabres.2025.112940_b0420","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1021\/bi00142a024","article-title":"Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments","volume":"31","author":"Rouy","year":"1992","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0425","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0037-1615654","article-title":"Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation","volume":"85","author":"Mart\u00ednez","year":"2001","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0430","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0435","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0440","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/ATVBAHA.121.317335","article-title":"Apo(a) and ApoB interact noncovalently within hepatocytes: implications for regulation of Lp(a) levels by modulation of ApoB secretion","volume":"42","author":"Youssef","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112940_b0445","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.diabres.2025.112940_b0450","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1172\/JCI112345","article-title":"Fat feeding in humans induces lipoproteins of density less than 1.006 that are enriched in apolipoprotein [a] and that cause lipid accumulation in macrophages","volume":"77","author":"Bersot","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.diabres.2025.112940_b0455","doi-asserted-by":"crossref","unstructured":"Gaubatz JW, Hoogeveen RC, Hoffman AS, Ghazzaly KG, Pownall HJ, Guevara J, Jr., et al. Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins. J Lipid Res 2001;42(12):2058-68. S0022-2275(20)31535-2.","DOI":"10.1016\/S0022-2275(20)31535-2"},{"issue":"2","key":"10.1016\/j.diabres.2025.112940_b0460","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.diabres.2025.112940_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154887","article-title":"Unravelling lipoprotein metabolism with stable isotopes: tracing the flow","volume":"124","author":"Ying","year":"2021","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0470","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/ATVBAHA.119.313877","article-title":"VLDL (very-low-density lipoprotein)-apo E (apolipoprotein E) may influence Lp(a) (lipoprotein [a]) synthesis or assembly","volume":"40","author":"Croyal","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.diabres.2025.112940_b0475","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.metabol.2019.04.010","article-title":"Fractional turnover of apolipoprotein(a) and apolipoprotein B-100 within plasma lipoprotein(a) particles in statin-treated patients with elevated and normal Lp(a) concentration","volume":"96","author":"Ma","year":"2019","journal-title":"Metabolism"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0480","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1210\/jc.2019-01382","article-title":"Apolipoprotein(a) kinetics in statin-treated patients with elevated plasma lipoprotein(a) concentration","volume":"104","author":"Ma","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"27","key":"10.1016\/j.diabres.2025.112940_b0485","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0490","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabres.2025.112940_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0500","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/joim.13457","article-title":"PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients with very high apolipoprotein(a) concentration","volume":"291","author":"Ying","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.diabres.2025.112940_b0505","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0510","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin Chem"},{"issue":"32","key":"10.1016\/j.diabres.2025.112940_b0515","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.diabres.2025.112940_b0520","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.numecd.2018.05.010","article-title":"Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus","volume":"28","author":"Zhang","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.diabres.2025.112940_b0525","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US family heart database","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijcard.2010.02.021","article-title":"Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women","volume":"150","author":"Qasim","year":"2011","journal-title":"Int J Cardiol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0535","article-title":"Cardiovascular events and sex differences: a single cardiological unit experience","volume":"12","author":"Pino","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0540","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11745-010-3513-1","article-title":"Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes","volume":"46","author":"Nakhjavani","year":"2011","journal-title":"Lipids"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0545","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00330-024-11313-2","article-title":"Impact of lipoprotein (a) on coronary atherosclerosis and plaque progression in patients with type 2 diabetes mellitus","volume":"35","author":"Lan","year":"2025","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0550","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12933-024-02348-2","article-title":"Lipoprotein(a) as a cardiovascular risk factor among patients with and without diabetes mellitus: the mass general brigham Lp(a) registry","volume":"23","author":"Shiyovich","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.diabres.2025.112940_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119179","article-title":"Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: the multi-ethnic study of atherosclerosis (MESA)","volume":"404","author":"Rikhi","year":"2025","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.diabres.2025.112940_b0560","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035353","article-title":"Sex differences in the association between lipoprotein(a) and cardiovascular outcomes: the MGB Lp(a) registry","volume":"14","author":"Kaur","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0565","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1210\/jc.2016-4015","article-title":"Association between serum lipoprotein(a) and diabetic retinopathy in han chinese patients with type 2 diabetes","volume":"102","author":"Tu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.diabres.2025.112940_b0570","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0026-0495(92)90152-Z","article-title":"Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the wisconsin epidemiologic study of diabetic retinopathy","volume":"41","author":"Haffner","year":"1992","journal-title":"Metabolism"},{"issue":"10","key":"10.1016\/j.diabres.2025.112940_b0575","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.numecd.2020.05.011","article-title":"Lp(a) and apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: a case-cohort study","volume":"30","author":"Moosaie","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.diabres.2025.112940_b0580","article-title":"Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes","volume":"14","author":"Li","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0585","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1007\/s00125-020-05120-9","article-title":"Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus","volume":"63","author":"Singh","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0590","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0595","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1373\/clinchem.2017.277103","article-title":"Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with kringle IV type 2 repeats","volume":"63","author":"Tolbus","year":"2017","journal-title":"Clin Chem"},{"issue":"24","key":"10.1016\/j.diabres.2025.112940_b0600","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0605","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2025.112940_b0610","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.athplu.2024.07.001","article-title":"Associations of very low Lipoprotein(a) levels with risks of new-onset diabetes and non-alcoholic liver disease","volume":"57","author":"Yeung","year":"2024","journal-title":"Atherosclerosis Plus"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0615","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1194\/jlr.P049015","article-title":"Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly chinese population","volume":"56","author":"Ding","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.diabres.2025.112940_b0620","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5743838","article-title":"Serum lipoprotein (a) levels in black South African type 2 diabetes mellitus patients","volume":"2016","author":"Joseph","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.diabres.2025.112940_b0625","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fendo.2017.00204","article-title":"Disparities in cardiovascular disease and type 2 diabetes risk factors in blacks and whites: dissecting racial paradox of metabolic syndrome","volume":"8","author":"Osei","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.diabres.2025.112940_b0630","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.5114\/aoms\/187774","article-title":"Association between Lp(a) and T2D: a Mendelian randomization study","volume":"20","author":"Go\u0142awski","year":"2024","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.diabres.2025.112940_b0635","doi-asserted-by":"crossref","unstructured":"Mu-Han-Ha-Li \u8fea\u4e3d\u8fbe\u5c14 \u6728\u6c57\u54c8\u529b DL, Zhai \u7fdf\u5929\u7fbd TY, Ling \u51cc\u96c1 Y, Gao \u9ad8\u946b X. LPA kringle IV type 2 is associated with type 2 diabetes in a Chinese population with very high cardiovascular risk. Journal of lipid research 2018;59(5):884-91. 10.1194\/jlr.P082792.","DOI":"10.1194\/jlr.P082792"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0640","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s001250051110","article-title":"Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes","volume":"42","author":"Neele","year":"1999","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0645","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1590\/S0066-782X2009000700006","article-title":"Lipoprotein (a) is associated with basal insulin levels in patients with type 2 diabetes mellitus","volume":"93","author":"Habib","year":"2009","journal-title":"Arq Bras Cardiol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0650","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12933-024-02389-7","article-title":"Causal associations between insulin and Lp(a) levels in Caucasian population:a Mendelian randomization study","volume":"23","author":"Lejawa","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.diabres.2025.112940_b0655","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177500","article-title":"Insulin resistance contributes more to the increased risk for diabetes development in subjects with low lipoprotein(a) level than insulin secretion","volume":"12","author":"Rhee","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.diabres.2025.112940_b0660","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.ATV.18.8.1335","article-title":"Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype","volume":"18","author":"Rainwater","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112940_b0665","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/00325481.2017.1342508","article-title":"Lipoprotein(a)-activated immunity, insulin resistance and new-onset diabetes","volume":"129","author":"Kaya","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.diabres.2025.112940_b0670","article-title":"Association between lipoprotein(a) and insulin resistance in chinese adults: results from the China health and nutrition survey","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.diabres.2025.112940_b0675","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00592-017-1036-4","article-title":"Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin","volume":"54","author":"Buchmann","year":"2017","journal-title":"Acta Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0680","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2013-04-494641","article-title":"Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity","volume":"122","author":"Ajjan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.diabres.2025.112940_b0685","doi-asserted-by":"crossref","unstructured":"Abdullah FE, Ahmed SN. Serum lipoprotein(a), and plasminogen activator inhibitor-1 in uncomplicated type 2 diabetes mellitus: a case-control study. Ann Med Surg (2012) 2023;85(8):3801-5. 10.1097\/ms9.0000000000000915.","DOI":"10.1097\/MS9.0000000000000915"},{"key":"10.1016\/j.diabres.2025.112940_b0690","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-11-1","article-title":"Plasminogen activator inhibitor-1 4G\/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis","volume":"11","author":"Zhang","year":"2013","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.diabres.2025.112940_b0695","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00431-025-06278-3","article-title":"Urinary plasminogen as an early marker of diabetic kidney disease in children with type 1 diabetes mellitus: a cross-sectional study","volume":"184","author":"\u0130n\u00f6z\u00fc","year":"2025","journal-title":"Eur J Pediatr"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0700","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.amjmed.2023.06.030","article-title":"Optimal prescribing of statins to reduce cardiovascular disease","volume":"136","author":"Schade","year":"2023","journal-title":"Am J Med"},{"issue":"24","key":"10.1016\/j.diabres.2025.112940_b0705","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0710","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12933-023-01857-w","article-title":"Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study","volume":"22","author":"Yu","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0715","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-021-01287-6","article-title":"Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON","volume":"20","author":"Lorenzatti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112940_b0720","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-0991-1","article-title":"Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol","volume":"19","author":"Colhoun","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112940_b0725","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc24-2110","article-title":"Risk of incident diabetes related to lipoprotein(a), LDL cholesterol, and their changes with alirocumab: post hoc analyses of the ODYSSEY OUTCOMES randomized trial","volume":"48","author":"Schwartz","year":"2025","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.diabres.2025.112940_b0730","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.diabres.2025.112940_b0735","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.numecd.2023.05.033","article-title":"Efficacy and safety of PCSK9 inhibitors in patients with diabetes: a systematic review and meta-analysis","volume":"33","author":"Chen","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.diabres.2025.112940_b0740","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MED.0000000000000597","article-title":"Lipoprotein (a) and diabetes mellitus: causes and consequences","volume":"28","author":"Ward","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.diabres.2025.112940_b0745","doi-asserted-by":"crossref","DOI":"10.1097\/MOL.0000000000000996","article-title":"Are lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes?","author":"Corral","year":"2025","journal-title":"Curr Opin Lipidol"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:18:12Z","timestamp":1773184692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":149,"alternative-id":["S0168822725009544"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112940","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Between Scylla and Charybdis \u2013 Enigmatic role of lipoprotein(a) in atherosclerotic cardiovascular disease and type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112940"}}